D-BSSE spinoff Memo Therapeutics secures funding to speed up clinical development of therapeutic antibodies for renal transplant patients

Memo Therapeutics, a late-stage biotech company specialised in the development of therapeutic antibodies, has announced the successful closure of a CHF 25 million Series C financing round. The raised capital will be instrumental to complete the Phase 2 clinical development of the antibody AntiBKV, designed to combat BK polyomavirus infections in kidney transplant recipients. Founded in 2012, Memo Therapeutics originated from the Bioprocess lab of Sven Panke.